Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Barchart Premier: The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Reshape Lifesciences Inc (RSLS)

Reshape Lifesciences Inc (RSLS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 3,121
  • Shares Outstanding, K 713
  • Annual Sales, $ 8,680 K
  • Annual Income, $ -11,390 K
  • EBIT $ -8 M
  • EBITDA $ -8 M
  • 60-Month Beta 1.41
  • Price/Sales 0.36
  • Price/Cash Flow N/A
  • Price/Book 1.52

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 1 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/18
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year -1,182.51
  • Growth Rate Est. (year over year) +184.48%

Price Performance

See More
Period Period Low Period High Performance
1-Month
4.09 +7.09%
on 12/17/24
5.94 -26.26%
on 11/29/24
-0.66 (-13.10%)
since 11/20/24
3-Month
4.09 +7.09%
on 12/17/24
12.13 -63.89%
on 09/23/24
-2.12 (-32.57%)
since 09/20/24
52-Week
4.09 +7.09%
on 12/17/24
29.00 -84.90%
on 05/29/24
-13.37 (-75.32%)
since 12/20/23

Most Recent Stories

More News
ReShape Lifesciences® Reports Third Quarter Ended September 30, 2024 Financial Results and Provides Corporate Update

RSLS : 4.38 (-2.01%)
ReShape Lifesciences® to Announce Financial Results for the Third Quarter Ended September 30, 2024, and Provide Corporate Update

RSLS : 4.38 (-2.01%)
ReShape Lifesciences® Receives Health Canada Approval for its Next-Generation Lap-Band® 2.0 FLEX

RSLS : 4.38 (-2.01%)
ReShape Lifesciences® Receives NIH Supplementary Grant with the University of Southern California’s Center for Autonomic Nerve Recording and Stimulation Systems (CARSS) to Further Develop Next-Generation Electrodes for ReShape’s Proprietary...

RSLS : 4.38 (-2.01%)
ReShape Lifesciencesâ„¢ to Announce Financial Results for the Second Quarter Ended June 30, 2022 and Provide Corporate Update

Conference Call to be Held at 4:30 pm ET on Monday, August 15 , 2022...

RSLS : 4.38 (-2.01%)
ReShape Lifesciencesâ„¢ Receives FDA 510(k) Clearance for the GIBI HDâ„¢ Calibration Tubes for use in Gastric and Bariatric Procedures

New Calibration Tubes, in Three Sizes, Will Simplify Gastric and Bariatric Procedures Including Laparoscopic Sleeve Gastrectomy, Gastric Bypass and Gastric...

RSLS : 4.38 (-2.01%)
ReShape Lifesciences Announces Appointment of Paul F. Hickey as President and Chief Executive Officer

SAN CLEMENTE, Calif., July 27, 2022 (GLOBE NEWSWIRE) -- ReShape Lifesciencesâ„¢ (Nasdaq: RSLS), the premier physician-led weight loss and metabolic health...

RSLS : 4.38 (-2.01%)
ReShape Lifesciences Enters into Warrant Exercise Transaction for $2.5 Million in Gross Proceeds

SAN CLEMENTE, Calif., June 17, 2022 (GLOBE NEWSWIRE) -- ReShape Lifesciences Inc. (Nasdaq: RSLS), the premier physician-led weight loss and metabolic...

RSLS : 4.38 (-2.01%)
ReShape Lifesciences and OpenLoop Sign Agreement to Provide Nationwide Virtual Health Services for Weight Loss and Wellness Through reshapecareâ„¢

Solution will Provide Physician-Led Virtual Weight Loss Coaching...

RSLS : 4.38 (-2.01%)
ReShape Lifesciencesâ„¢ Reports First Quarter 2022 Financial Results and Provides Corporate Update

March 2022 Revenues Exceeded January’s and February’s, Combined, Indicating DTC Campaign and Other Visibility Activities are Driving Significant Demand for...

RSLS : 4.38 (-2.01%)

Business Summary

ReShape Lifesciences Inc. provides weight-loss solutions. It offers an integrated portfolio of proven products and services which manage and treat obesity and metabolic disease. ReShape Lifesciences Inc., formerly known as Obalon Therapeutics, is based in SAN CLEMENTE, CA.

See More

Key Turning Points

3rd Resistance Point 5.04
2nd Resistance Point 4.86
1st Resistance Point 4.62
Last Price 4.38
1st Support Level 4.21
2nd Support Level 4.03
3rd Support Level 3.79

See More

52-Week High 29.00
Fibonacci 61.8% 19.48
Fibonacci 50% 16.55
Fibonacci 38.2% 13.61
Last Price 4.38
52-Week Low 4.09

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar